Stock Ratings / Health Care / APMD / forecast

WVE (32) GYRE (46) SGMT (34) DSGN (45) ⌘ Pro Terminal →

Apnimed Inc. (APMD) 12-Month Stock Forecast & Price Target Cone

$17.34 -9.45% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $17.01

Apnimed Inc. (APMD) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $721.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $17.01 (-1.89%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 0.5% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for APMD)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (47/100 Composite)

🔍 WHY APMD SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+10/20 pts (21% of score)

SEC XBRL FY 2025 (10-K): 0.5% FCF Margin ($20.2M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$18.52-4.1% Next Q

Q2 (-2Q)

Grade C-$17.76+6.9% Next Q

Q3 (-1Q)

Grade C-$18.99-8.7% Next Q

Current

Grade D$17.34-5.9% Hist 90D α

Trajectory: C (55) → D (47)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a APMD Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While APMD currently carries a cautious 47/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($22.93) and Max Pain ($18.21) forces dealer call-delta covering toward $37.05.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $APMD• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “APMD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 47%NO 53%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your APMD Position Size: $10,000

Shares at $17.34: 576.7 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $12.85

$7,411

$-2,589 (-25.9%)

12M Consensus BaseTarget $16.48

$9,504

$-496 (-5.0%)

12M Bull Case BreakoutTarget $37.05

$21,367

+$11,367 (+113.7%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$17	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$35	69%	B
JP MorganUS Large-Cap Research	SELL	$15	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring APMD)

✓Walkthrough of APMD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

APMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -30.64%▼ DESCENDING CHANNEL

2026-10-30O $17.10H $17.36L $16.16C $17.34VOL 466.0K

RES: $19.05SUP: $15.40SMA50: $22.93SMA200: $24.13

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

APMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 APMD Butterfly Map → + Track APMD →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on APMD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for APMD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for APMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (APMD)

Health Care Rank #407 of 1016 ⚔️ WVE vs APMD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (APMD vs. WVE, GYRE, SGMT, DSGN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Apnimed Inc. (APMD) ranks #407 by composite RQD confidence (47/100, grade D) and #396 by equity capitalization ($721.9M). Within this direct 5-issuer industry benchmark cohort, GYRE leads on earnings valuation at 72.3x trailing P/E, while GYRE leads on capital efficiency and profitability with 25.4% ROIC and 95.4% gross margin. APMD currently leads its immediate peer cohort in composite quantitative strength at 47/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
APMD ACTIVE Apnimed Inc.	D	47/100	—	—	—	-9.45%	$721.9M	Benchmark Subject
WVE Wave Life Sciences Inc.	E	32/100	—	—	-35.0%	-0.28%	$715.9M	/wve-vs-apmd →
GYRE Gyre Therapeutics Inc.	D	46/100	72.3x	95.4%	25.4%	-9.59%	$714.8M	/gyre-vs-apmd →
SGMT Sagimet Biosciences Inc. (Series A)	E	34/100	—	—	-35.0%	-2.89%	$735.7M	/sgmt-vs-apmd →
DSGN Design Therapeutics Inc.	D	45/100	—	—	-32.1%	-0.18%	$692.2M	/dsgn-vs-apmd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001745648

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Apnimed Inc. (APMD) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, APMD closed FY2025 with $72.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$0	—	—	$72.9M	$0

3. APMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is APMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Apnimed Inc. (NASDAQ: APMD) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $17.34 (-9.45% 1D, market cap $721.9M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, APMD ranks #407 in composite RQD confidence.

How does APMD compare to WVE and GYRE in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), APMD carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, WVE (Wave Life Sciences Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $715.9M) and GYRE (Gyre Therapeutics Inc.) posts a D grade (46/100 RQD, P/E 72.3x, ROIC 25.4%, cap $714.8M). Among the 5-stock peer group, GYRE leads on earnings multiple (72.3x) while GYRE leads on capital efficiency (25.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for APMD?

Per APMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001745648), Apnimed Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $72.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is APMD trading relative to its 50-day, 200-day, and 52-week technical levels?

APMD last traded at $17.34 (-9.45% on volume of 1,011,759 shares), positioning the stock -24.38% below its 50-day simple moving average ($22.93) and -28.14% below its 200-day simple moving average ($24.13). Across its 52-week range of $16.12 to $35.29, APMD sits at the 6.4% percentile with a 14-day RSI of 35.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($15.17 to $19.51).

APMD Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is APMD's 12-month stock price target?

Apnimed Inc. (APMD) carries a 12-month consensus base price target of $16.48 (-5% from $17.34), with a bull-case target of $37.05 and a bear-case floor of $12.85.

Is APMD stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates APMD D (Sell — SELL) with an RQD Confidence score of 47/100.

Direct Sub-Reports: APMD RQD Cockpit APMD 12M Forecast APMD Earnings & Move APMD Dividends & DRIP APMD Insiders & 13F APMD Whale Options APMD Profit Sankey APMD News & Why